HUM GENET 润色咨询

HUMAN GENETICS

出版年份：1976 年文章数：1893 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：3.4% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2022-12-15 花荣 来自安徽省

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向：基因功能;临床
    经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2020-05-01 da-xiang

    审稿速度:3.0 | 投稿命中率:25.0
    经验分享：记录一下投稿过程
    2019.10.14 Submit
    2019.10.14 New Submition
    2019.10.15 Editor Assigned
    2019.10.16 Under Review
    2019.10.18 Under Review
    2019.11.10 Reviewers Assigned
    2019.11.12 Reviewers Assigned
    2019.11.14 Under Review
    2019.12.4 Reviews Completed
    2019.12.5 Minor Revision
    2019.12.12 Revision Submitted
    2019.12.13 Reviewers Assigned
    2019.12.13 Under Review
    2019.12.15 Under Review
    2020.1.6 Accept
    2020.2.4 Published
    投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2021-12-27 小动量

    上传文章有什么要求？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2021-12-27 乌云背后的幸福线

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2019-10-30 da-xiang

    今年又蹦到5.2了，继续保持啊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2018-11-07 ms5704996609785591

    审稿速度:4.0
    经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2018-06-27 1e1262fam48(暂无匿称)

    这是降到3.9了吗

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2018-04-27 1228f0e8m40(暂无昵称)

    请问human genetics的short communication格式是啥呀？谁投过稿求指导

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2016-07-15 蕾蕾1995

    我的11号投的，一直就是editor assignment的状态就没变过怎么回事？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2106168, encodeId=2d59210616809, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：基因功能;临床<br>经验分享：杂志反应很快，同级别的杂志中，可以优先投这个。投过两篇，无论是初投还是回修，都是第一天投第二天就有反应了。两篇从投到接收，都是1个半月以内。杂志口碑也还行。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/3E0BE9C71EBC40D4C7B716EC3D4D6BAF/100, createdBy=83c02327046, createdName=花荣, createdTime=Thu Dec 15 12:32:42 CST 2022, time=2022-12-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=590042, encodeId=ad97590042f7, content=审稿速度:3.0 | 投稿命中率:25.0<br>经验分享：记录一下投稿过程 <br> 2019.10.14 Submit <br> 2019.10.14 New Submition <br> 2019.10.15 Editor Assigned <br> 2019.10.16 Under Review <br> 2019.10.18 Under Review <br> 2019.11.10 Reviewers Assigned <br> 2019.11.12 Reviewers Assigned <br> 2019.11.14 Under Review <br> 2019.12.4 Reviews Completed <br> 2019.12.5 Minor Revision <br> 2019.12.12 Revision Submitted <br> 2019.12.13 Reviewers Assigned <br> 2019.12.13 Under Review <br> 2019.12.15 Under Review <br> 2020.1.6 Accept <br> 2020.2.4 Published <br> 投稿之前先和主编写了一封Presubmission inquiry，主编如果对你的研究很感兴趣，那么投起来命中率就大很多了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Fri May 01 07:44:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091185, encodeId=e4c910911852d, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091186, encodeId=82151091186eb, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579078, encodeId=a5635e907872, content=今年又蹦到5.2了，继续保持啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Oct 30 15:02:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=848069, encodeId=11c984806966, content=审稿速度:4.0<br>经验分享：虽然目前还是2区，不过分都降了那么多了，明年不会掉到三区去吧？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8155414118, createdName=ms5704996609785591, createdTime=Wed Nov 07 16:12:22 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=558493, encodeId=34b55584937b, content=这是降到3.9了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=283, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161125/IMG5837E39E531196804.jpg, createdBy=de121956142, createdName=1e1262fam48(暂无匿称), createdTime=Wed Jun 27 00:00:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555469, encodeId=1682555469ab, content=请问human genetics的short communication格式是啥呀？谁投过稿求指导, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34f02341039, createdName=1228f0e8m40(暂无昵称), createdTime=Fri Apr 27 15:32:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=524820, encodeId=7b825248205d, content=我的11号投的，一直就是editor assignment的状态就没变过怎么回事？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=307, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de4c1642859, createdName=蕾蕾1995, createdTime=Fri Jul 15 11:54:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=508968, encodeId=88ed5089685b, content=杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=410, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Mon Jan 05 15:04:00 CST 2015, time=2015-01-05, status=1, ipAttribution=)]
    2015-01-05 匿名用户

    杂志专业性很强，如果文章内容稍有不符会很快被拒。建议投稿慎重。

    0

共21条页码: 1/3页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分